Saturday 17 October 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 26.7%, free cash flow fell 82.5% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.88
0.69
−2.42%
Follow VERA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
10.92 | 13.64 | 13.64 | 12.21 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.76 | 4.17 | 6.77 | 5.01 | |
Debt/Assets |
14.11% | 12.07% | 10.19% | 14.42% | |
Debt/Equity |
0.18 | 0.15 | 0.12 | 0.19 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 0.88 | 0.77 | 0.77 | |
Capex/Depreciation |
0.36 | 2.70 | 0.30 | 0.28 | |
Interest Coverage |
(60.87) | (68.64) | (49.45) | (42.82) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.40) | (1.49) | (1.09) | (0.97) | |
Cash per Share |
6.95 | 8.35 | 11.12 | 7.79 | |
Shareholders Equity per Share |
5.68 | 6.99 | 9.41 | 6.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.68 | 6.99 | 9.41 | 6.25 | |
Free Cash Flow |
(100.37) | (106.67) | (70.10) | (62.04) | |
Working Capital |
479.17 | 570.65 | 675.43 | 469.43 | |
Capital Expenditures |
(0.11) | (0.17) | (0.10) | (0.13) | |
Net Current Asset Value |
402.27 | 493.76 | 598.67 | 392.69 | |
| Other line items | |||||
Quick Ratio |
10.33 | 13.22 | 13.37 | 11.88 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.40) | (1.49) | (1.09) | (0.97) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
13.87 | 11.59 | 14.78 | 11.28 | |
Average Assets |
555.76 | 615.95 | 695.21 | 443.03 | |
Average Common Equity |
438.02 | 517.35 | 590.84 | 343.97 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates